February 23, 2023
A pair of researchers from Stanford University have published a detailed review of the current state of CAR T immune cell therapies in Nature. A new state of the art in fighting cancer Chimeric antigen receptor (CAR) is a technology that allows researchers to alter T cells to attack specifically chosen targets. As of this...
January 23, 2023
The results of a Phase 1 clinical trial of allogeneic CAR T cell therapy against multiple myeloma have been published today in Nature Medicine, and they appear to be promising. B cells, engineered T cells, and lymphodepletion Multiple myeloma is a cancer of the plasma B cells, which are formed in the blood marrow and...
December 12, 2022
A team of researchers from multiple Japanese universities has found a way to genetically enhance T cells against solid tumors, as published today in Nature Biomedical Engineering. A focus on signals This highly in-depth paper begins with a discussion of signaling in the response of chimeric antigen receptor (CAR) T cells, as good signals are...
October 28, 2022
Turn.bio has announced that its proprietary cellular reprogramming technology was able to significantly increase the proliferative and cytotoxic potential of premanufactured CAR-T cells in vitro. Turn.bio, a developer of mRNA-based cellular reprogramming technologies, has announced preliminary results from its current trial. The announcement was made by the company's co-founder, Prof. Vittorio Sebastiano, at the New...
May 10, 2022
In a pre-print paper, scientists have shown that treatment with NMN increases the survival and anti-cancer efficacy of CAR-T cells [1]. The problem with immunotherapy T cells are a central element of the adaptive immune system, and some of them can be cytotoxic: they have the ability to kill other cells. This lets us get...
January 21, 2022
Hosted by Dr. Oliver Medvedik, Journal Club returns on Tuesday 25th January at 12:00 Eastern and will be broadcast live on the Lifespan.io Facebook page. The topic for this month is the paper 'CAR T cells produced in vivo to treat cardiac injury', which looks at how researchers created CAR T cells to target scar...
